Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Even among patients with prostate cancer liver metastasis who have a poor prognosis, elevated ctDNA fraction and tumor suppressor gene loss differentiate survival.

Bayer on April 1 showcased significant advancements in its pharmaceutical growth strategy and pipeline at its annual Pharma Media Day.As part of the ongoing transformation of its pharmaceutical ...